Tomoyuki Nagata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6573983/publications.pdf

Version: 2024-02-01

39 papers	602 citations	623734 14 h-index	642732 23 g-index
Papero			5 maon
39 all docs	39 docs citations	39 times ranked	975 citing authors

#	Article	IF	CITATIONS
1	Education level is associated with neuropsychiatric symptoms in patients with amnesticâ€mild cognitive impairment. Psychogeriatrics, 2022, 22, 343-352.	1.2	3
2	A case of V180I genetic mutation Creutzfeldt Jakob disease (CJD) with delusional misidentification as an initial symptom. Prion, 2022, 16 , $7-13$.	1.8	5
3	Suppressors of Cytokine Signaling Are Decreased in Major Depressive Disorder Patients. Journal of Personalized Medicine, 2022, 12, 1040.	2.5	6
4	Blood DNA Methylation Levels in the WNT5A Gene Promoter Region: A Potential Biomarker for Agitation in Subjects with Dementia. Journal of Alzheimer's Disease, 2021, 81, 1601-1611.	2.6	3
5	Sex differences in the severity of neuropsychiatric symptoms and their relationship with clinico-demographic and psychosocial factors in patients with amnestic mild cognitive impairment and mild Alzheimer's disease. Aging and Mental Health, 2020, 24, 431-438.	2.8	8
6	Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimer's disease. Scientific Reports, 2020, 10, 12217.	3.3	17
7	The timeâ€dependent trajectory of neuropsychiatric symptoms in patients with Alzheimer's disease. Psychogeriatrics, 2020, 20, 542-543.	1.2	1
8	Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Clinical Psychiatry, 2020, 81,	2.2	6
9	Anosognosia in patients with Alzheimer's disease: current perspectives. Psychogeriatrics, 2020, 20, 345-352.	1.2	14
10	Effects of neuropsychiatric symptoms of dementia on reductions in activities of daily living in patients with Alzheimer's disease. Geriatrics and Gerontology International, 2020, 20, 584-588.	1.5	8
11	Pharmacological management of behavioral disturbances in patients with Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2020, 21, 1093-1102.	1.8	7
12	Anosognosia in mild <scp>A</scp> lzheimer's disease is correlated with not only neural dysfunction but also compensation. Psychogeriatrics, 2018, 18, 81-88.	1.2	10
13	Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease, 2018, 66, 139-148.	2.6	13
14	Genetic association between <i>RAGE</i> polymorphisms and Alzheimer's disease and Lewy body dementias in a Japanese cohort: a caseâ€"control study. International Journal of Geriatric Psychiatry, 2017, 32, 1241-1246.	2.7	5
15	Psychosocial or clinicoâ€demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIEâ€AD study. International Journal of Geriatric Psychiatry, 2017, 32, 1264-1271.	2.7	27
16	Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease, 2017, 60, 263-272.	2.6	7
17	Genetic Association between Presenilin 2 Polymorphisms and Alzheimer's Disease and Dementia of Lewy Body Type in a Japanese Population. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 90-97.	1.3	2
18	Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer's Disease and Amnesic Mild Cognitive Impairment. PLoS ONE, 2016, 11, e0146449.	2.5	29

#	Article	IF	CITATIONS
19	Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer's Disease and Amnestic Mild Cognitive Impairment. PLoS ONE, 2016, 11, e0168816.	2.5	26
20	Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease, 2016, 50, 839-845.	2.6	19
21	Executive Dysfunction Correlated With 2-Year Treatment Response in Patients With Late-Life Undifferentiated Somatoform Disorders. Psychosomatics, 2016, 57, 378-389.	2.5	3
22	Cognitive Dysfunction in Patients With Late-Life Somatic Symptom Disorder: A Comparison According to Disease Severity. Psychosomatics, 2015, 56, 486-494.	2.5	9
23	Association between DNA Methylation of the BDNF Promoter Region and Clinical Presentation in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 64-73.	1.3	65
24	Association between the catecholâ€Oâ€methyltransferase polymorphism Val158Met and Alzheimer's disease in a Japanese population. International Journal of Geriatric Psychiatry, 2015, 30, 927-933.	2.7	4
25	Correlation between cognition and symptomatic severity in patients with late-life somatoform disorders. Aging and Mental Health, 2015, 19, 169-174.	2.8	4
26	Plasma BDNF levels are correlated with aggressiveness in patients with amnestic mild cognitive impairment or Alzheimer disease. Journal of Neural Transmission, 2014, 121, 433-441.	2.8	36
27	Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease. Biochemical and Biophysical Research Communications, 2013, 430, 907-911.	2.1	62
28	Age-Related Association between Apolipoprotein E e4 and Cognitive Function in Japanese Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 66-73.	1.3	2
29	A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease. International Psychogeriatrics, 2013, 25, 1199-1201.	1.0	21
30	Genetic Association between Neurotrophin-3 Polymorphisms and Alzheimer's Disease in Japanese Patients. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 272-280.	1.3	7
31	Association between BDNF Polymorphism (Val66Met) and Executive Function in Patients with Amnestic Mild Cognitive Impairment or Mild Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2012, 33, 266-272.	1.5	33
32	Association between Nerve Growth Factor Gene Polymorphism and Executive Dysfunction in Japanese Patients with Early-Stage Alzheimerâ∈™s Disease and Amnestic Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2011, 32, 379-386.	1.5	10
33	Association between executive dysfunction and hippocampal volume in Alzheimer's disease. International Psychogeriatrics, 2011, 23, 764-771.	1.0	33
34	Association between brainâ€derived neurotrophic factor (⟨i⟩BDNF⟨/i⟩) gene polymorphisms and executive function in Japanese patients with Alzheimer's disease. Psychogeriatrics, 2011, 11, 141-149.	1.2	15
35	Differentiation between amnesticâ€mild cognitive impairment and earlyâ€stage Alzheimer's disease using the Frontal Assessment Battery test. Psychogeriatrics, 2011, 11, 235-241.	1.2	17
36	Relationship of frontal lobe dysfunction and aberrant motor behaviors in patients with Alzheimer's disease. International Psychogeriatrics, 2010, 22, 463-469.	1.0	26

Tomoyuki Nagata

#	Article	IF	CITATIONS
37	Correlation between a reduction in Frontal Assessment Battery scores and delusional thoughts in patients with Alzheimer's disease. Psychiatry and Clinical Neurosciences, 2009, 63, 449-454.	1.8	25
38	Anorexia nervosa with chronic episodes for more than $30\hat{a} \in f$ years in a patient with a comorbid schizotypal personality disorder. Psychiatry and Clinical Neurosciences, 2007, 61, 434-436.	1.8	4
39	Effectiveness of carbamazepine for benzodiazepineâ€resistant impulsive aggression in a patient with frontal infarctions. Psychiatry and Clinical Neurosciences, 2007, 61, 695-697.	1.8	10